GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (TSX:ONC) » Definitions » Cyclically Adjusted Book per Share

Oncolytics Biotech (TSX:ONC) Cyclically Adjusted Book per Share : C$1.01 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Oncolytics Biotech Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Oncolytics Biotech's adjusted book value per share for the three months ended in Mar. 2024 was C$0.305. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$1.01 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Oncolytics Biotech's average Cyclically Adjusted Book Growth Rate was -22.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -21.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -17.80% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -15.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Oncolytics Biotech was -6.10% per year. The lowest was -21.20% per year. And the median was -13.90% per year.

As of today (2024-05-21), Oncolytics Biotech's current stock price is C$1.51. Oncolytics Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was C$1.01. Oncolytics Biotech's Cyclically Adjusted PB Ratio of today is 1.50.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Oncolytics Biotech was 2.48. The lowest was 0.00. And the median was 0.00.


Oncolytics Biotech Cyclically Adjusted Book per Share Historical Data

The historical data trend for Oncolytics Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Cyclically Adjusted Book per Share Chart

Oncolytics Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.59 2.17 1.69 1.42 1.06

Oncolytics Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.31 1.21 1.13 1.06 1.01

Competitive Comparison of Oncolytics Biotech's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Oncolytics Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Cyclically Adjusted PB Ratio falls into.



Oncolytics Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Oncolytics Biotech's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.305/126.2576*126.2576
=0.305

Current CPI (Mar. 2024) = 126.2576.

Oncolytics Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.778 99.473 2.257
201409 1.568 99.394 1.992
201412 1.404 98.367 1.802
201503 2.353 99.789 2.977
201506 2.432 100.500 3.055
201509 2.232 100.421 2.806
201512 1.984 99.947 2.506
201603 1.638 101.054 2.047
201606 1.485 102.002 1.838
201609 1.228 101.765 1.524
201612 0.838 101.449 1.043
201703 0.570 102.634 0.701
201706 0.974 103.029 1.194
201709 0.815 103.345 0.996
201712 0.555 103.345 0.678
201803 0.317 105.004 0.381
201806 0.664 105.557 0.794
201809 0.535 105.636 0.639
201812 0.356 105.399 0.426
201903 0.299 106.979 0.353
201906 0.186 107.690 0.218
201909 0.138 107.611 0.162
201912 -0.003 107.769 -0.004
202003 0.620 107.927 0.725
202006 0.588 108.401 0.685
202009 0.495 108.164 0.578
202012 0.536 108.559 0.623
202103 0.845 110.298 0.967
202106 0.846 111.720 0.956
202109 0.777 112.905 0.869
202112 0.656 113.774 0.728
202203 0.609 117.646 0.654
202206 0.532 120.806 0.556
202209 0.484 120.648 0.507
202212 0.432 120.964 0.451
202303 0.402 122.702 0.414
202306 0.338 124.203 0.344
202309 0.395 125.230 0.398
202312 0.370 125.072 0.374
202403 0.305 126.258 0.305

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Oncolytics Biotech  (TSX:ONC) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Oncolytics Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.51/1.01
=1.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Oncolytics Biotech was 2.48. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Oncolytics Biotech Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (TSX:ONC) Business Description

Industry
Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.
Executives
Kirk Look Senior Officer

Oncolytics Biotech (TSX:ONC) Headlines

No Headlines